PTHS · Insider Trading
Pelthos Therapeutics Inc.
Every open-market purchase and sale reported by PTHS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-06 | Ezra M Friedberg | Director | Sell | −558 | −$11.56K |
| 2026-10-06 | Peter Greenleaf | Director | Sell | −797 | −$16.87K |
| 2026-10-06 | Matthew Pauls | Director | Sell | −786 | −$16.51K |
| 2026-07-07 | Matthew Pauls | Director | Sell | −786 | −$20.56K |
| 2026-07-07 | Peter Greenleaf | Director | Sell | −797 | −$20.83K |
| 2026-07-07 | Ezra M Friedberg | Director | Sell | −558 | −$14.56K |
| 2026-06-17 | Ezra M Friedberg | Director | Sell | −283 | −$7.72K |
| 2026-06-15 | Todd C Davis | Director | Buy | +35,948 | +$999.98K |
| 2026-05-26 | Knuettel Francis II | CFO, Treas & Secty | MIXED | −15,447 | −$40.26K |
| 2026-05-18 | Ezra M Friedberg | Director | F | −144 | −$3.89K |
| 2026-04-06 | Matthew Pauls | Director | Sell | −786 | −$16.44K |
| 2026-04-06 | Ezra M Friedberg | Director | Sell | −558 | −$11.67K |
| 2026-04-06 | Richard Malamut | Director | Sell | −590 | −$12.34K |
| 2026-04-06 | Peter Greenleaf | Director | Sell | −797 | −$16.67K |
| 2026-04-01 | Richard Malamut | Director | A | +28,012 | — |
| 2026-04-01 | Scott M. Plesha | CEO and President | A | +83,678 | — |
| 2026-04-01 | Knuettel Francis II | CFO, Treas & Secty | A | +33,472 | — |
| 2026-04-01 | Richard B Baxter | Director | A | +19,108 | — |
| 2026-04-01 | Peter Greenleaf | Director | A | +25,478 | — |
| 2026-04-01 | Matthew Pauls | Director | A | +25,478 | — |
| 2026-04-01 | Ezra M Friedberg | Director | A | +28,012 | — |
| 2026-04-01 | Todd C Davis | Director | A | +36,969 | — |
| 2026-04-01 | Sai Rangarao | Chief Commercial Officer | A | +30,518 | — |
| 2025-12-29 | Andrew J. Einhorn | Director | A | +12,000 | — |
| 2025-12-19 | LIGAND PHARMACEUTICALS INC | Director | MIXED | — | — |
| 2025-12-12 | Matthew Pauls | Director | MIXED | +1,074 | — |
| 2025-11-26 | Ezra M Friedberg | Director | Sell | −10,000 | −$280.28K |
| 2025-11-10 | LIGAND PHARMACEUTICALS INC | Director | A | — | — |
| 2025-07-23 | Scott M. Plesha | CEO and President | A | +338,678 deriv. | — |
| 2025-07-21 | Sai Rangarao | Chief Commercial Officer | A | +123,518 deriv. | — |
| 2025-07-07 | Richard B Baxter | Director | A | +77,338 deriv. | — |
| 2025-07-07 | Knuettel Francis II | CFO, Treas & Secty | A | +135,472 deriv. | — |
| 2025-07-07 | Ezra M Friedberg | Director | A | +77,338 deriv. | — |
| 2025-07-07 | Peter Greenleaf | Director | A | +103,118 deriv. | — |
| 2025-07-07 | Todd C Davis | Director | A | +77,338 deriv. | — |
| 2025-07-07 | Richard Malamut | Director | A | +77,338 deriv. | — |
| 2025-07-07 | Matthew Pauls | Director | A | +103,118 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Todd C Davis | Director | 1,575,834 | $15.00M |
| Ezra M Friedberg | Director | 120,484 | $1.15M |
| Scott M. Plesha | CEO and President | 83,678 | $796.61K |
| Knuettel Francis II | CFO, Treas & Secty | 30,841 | $293.61K |
| Sai Rangarao | Chief Commercial Officer | 30,518 | $290.53K |
| Richard Malamut | Director | 28,742 | $273.62K |
| Peter Greenleaf | Director | 23,087 | $219.79K |
| Richard B Baxter | Director | 19,108 | $181.91K |
| Matthew Pauls | Director | 13,578 | $129.26K |
| Andrew J. Einhorn | Director | 12,000 | $114.24K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PTHS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.